- Home
- LIPO vs UOKA Comparison
LIPO vs UOKA Comparison
Compare LIPO & UOKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIPO
- UOKA
- Stock Information
- Founded
- LIPO 2005
- UOKA 2002
- Country
- LIPO United States
- UOKA United Kingdom
- Employees
- LIPO N/A
- UOKA N/A
- Industry
- LIPO Biotechnology: Pharmaceutical Preparations
- UOKA
- Sector
- LIPO Health Care
- UOKA
- Exchange
- LIPO Nasdaq
- UOKA NYSE
- Market Cap
- LIPO 3.5M
- UOKA 3.7M
- IPO Year
- LIPO 2022
- UOKA N/A
- Fundamental
- Price
- LIPO $2.66
- UOKA $0.26
- Analyst Decision
- LIPO Strong Buy
- UOKA
- Analyst Count
- LIPO 1
- UOKA 0
- Target Price
- LIPO $16.00
- UOKA N/A
- AVG Volume (30 Days)
- LIPO 169.2K
- UOKA 15.6M
- Earning Date
- LIPO 11-14-2024
- UOKA 02-16-2025
- Dividend Yield
- LIPO N/A
- UOKA N/A
- EPS Growth
- LIPO N/A
- UOKA N/A
- EPS
- LIPO N/A
- UOKA N/A
- Revenue
- LIPO $483,533.00
- UOKA $114,849.00
- Revenue This Year
- LIPO N/A
- UOKA N/A
- Revenue Next Year
- LIPO N/A
- UOKA N/A
- P/E Ratio
- LIPO N/A
- UOKA N/A
- Revenue Growth
- LIPO 0.78
- UOKA 289.97
- 52 Week Low
- LIPO $2.21
- UOKA $0.14
- 52 Week High
- LIPO $12.00
- UOKA $1.90
- Technical
- Relative Strength Index (RSI)
- LIPO 45.43
- UOKA N/A
- Support Level
- LIPO $2.53
- UOKA N/A
- Resistance Level
- LIPO $2.79
- UOKA N/A
- Average True Range (ATR)
- LIPO 0.29
- UOKA 0.00
- MACD
- LIPO -0.01
- UOKA 0.00
- Stochastic Oscillator
- LIPO 12.62
- UOKA 0.00
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
About UOKA MDJM LTD
MDJM Ltd is a real estate service company. The company provides real estate agency services to real estate developer clients, as well as real estate consulting services and independent training services on an as-needed basis. It offers consulting, marketing planning, advertising services, and sales strategies to real estate clients. The company income is derived from commission-based services and minimal consulting and other services. The company has two operating segments; the real estate agent services segment and the hospitality business segment. It derives a majority of its revenue from the People's Republic of China.